Compare Stocks: XLO, YDES, TARA, and ARCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.45 +22.4%	$7.09	$5.50 ▼ $24.17	$382.29M	2.39	879,736 shs	2.85 million shs
TARA Protara Therapeutics	$3.85 -1.3%	$4.03	$3.02 ▼ $7.82	$227.52M	1.5	385,663 shs	238,158 shs
XLO Xilio Therapeutics	$9.23	$9.04	$6.47 ▼ $12.74	$60.74M	-0.14	17,081 shs	5,225 shs
YDES YD Bio	$4.69 -2.1%	$2.55	$1.70 ▼ $25.00	$332M	N/A	46,764 shs	35,548 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+63.43%	+132.30%	+91.32%	-22.52%
TARA Protara Therapeutics	0.00%	-3.02%	-4.70%	-21.75%	+27.06%
XLO Xilio Therapeutics	0.00%	+0.65%	+11.07%	+11.88%	-0.65%
YDES YD Bio	0.00%	+57.38%	+129.90%	-1.26%	+468,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.45 +22.4%	$7.09	$5.50 ▼ $24.17	$382.29M	2.39	879,736 shs	2.85 million shs
TARA Protara Therapeutics	$3.85 -1.3%	$4.03	$3.02 ▼ $7.82	$227.52M	1.5	385,663 shs	238,158 shs
XLO Xilio Therapeutics	$9.23	$9.04	$6.47 ▼ $12.74	$60.74M	-0.14	17,081 shs	5,225 shs
YDES YD Bio	$4.69 -2.1%	$2.55	$1.70 ▼ $25.00	$332M	N/A	46,764 shs	35,548 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+63.43%	+132.30%	+91.32%	-22.52%
TARA Protara Therapeutics	0.00%	-3.02%	-4.70%	-21.75%	+27.06%
XLO Xilio Therapeutics	0.00%	+0.65%	+11.07%	+11.88%	-0.65%
YDES YD Bio	0.00%	+57.38%	+129.90%	-1.26%	+468,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.60	Moderate Buy	$20.00	48.70% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	581.82% Upside
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XLO, YDES, TARA, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TARA Protara Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/26/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	4.66	N/A	N/A	$6.04 per share	2.23
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$2.73 per share	N/A
XLO Xilio Therapeutics	$43.77M	1.39	N/A	N/A	$10.98 per share	0.84
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	11/9/2026 (Estimated)
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest XLO, YDES, TARA, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/6/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
TARA Protara Therapeutics	N/A	10.97	10.97
XLO Xilio Therapeutics	N/A	4.25	4.25
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
TARA Protara Therapeutics	38.13%
XLO Xilio Therapeutics	54.29%
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
TARA Protara Therapeutics	7.60%
XLO Xilio Therapeutics	7.45%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
TARA Protara Therapeutics	30	59.10 million	54.60 million	Optionable
XLO Xilio Therapeutics	70	6.58 million	6.09 million	Not Optionable
YDES YD Bio	N/A	70.79 million	N/A	N/A

XLO, YDES, TARA, and ARCT Headlines

Recent News About These Companies

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

YD Bio Ltd.

June 25, 2026 | barrons.com

Yd Bio

June 25, 2026 | fool.com

YD Bio Analyst Ratings and Price Targets | NASDAQ:YDES | Benzinga

June 25, 2026 | benzinga.com

YD Bio Limited Reports Financial Results for Full Year 2025, Achieves 17% Revenue Growth and Strategic Advances in Healthcare Innovations

April 30, 2026 | quiverquant.comQ

YD Bio Limited Reports Full Year 2025 Financial Results

April 30, 2026 | globenewswire.com

YD Bio Ltd YDES

April 4, 2026 | morningstar.comM

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

March 31, 2026 | globenewswire.com

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

March 17, 2026 | globenewswire.com

YD Bio Forms Taiwan-U.S. Dual-Core FDA Regulatory Platform in Alliance with YC Biotech

February 26, 2026 | tipranks.com

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

February 25, 2026 | globenewswire.com

YDES YD Bio Limited

February 25, 2026 | seekingalpha.com

YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC

January 30, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, YDES, TARA, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.45 +2.46 (+22.38%)

As of 08/21/2026 04:00 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Protara Therapeutics NASDAQ:TARA

$3.85 -0.05 (-1.28%)

As of 08/21/2026 04:00 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Xilio Therapeutics NASDAQ:XLO

$9.23 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

YD Bio NASDAQ:YDES

$4.69 -0.10 (-2.09%)

As of 08/21/2026 04:00 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XLO, YDES, TARA, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XLO, YDES, TARA, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XLO, YDES, TARA, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, YDES, TARA, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Protara Therapeutics NASDAQ:TARA

Xilio Therapeutics NASDAQ:XLO

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XLO, YDES, TARA, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XLO, YDES, TARA, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XLO, YDES, TARA, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, YDES, TARA, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Protara Therapeutics NASDAQ:TARA

Xilio Therapeutics NASDAQ:XLO

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools